Genetic Technologies (NASDAQ:GENE) & Adverum Biotechnologies (NASDAQ:ADVM) Financial Analysis

Adverum Biotechnologies (NASDAQ:ADVM) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Volatility & Risk

Adverum Biotechnologies has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Earnings & Valuation

This table compares Adverum Biotechnologies and Genetic Technologies’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adverum Biotechnologies	$3.60 million	43.83	-$117.17 million	($10.20)	-0.75
Genetic Technologies	$5.85 million	1.61	-$7.91 million	N/A	N/A

Genetic Technologies has higher revenue and earnings than Adverum Biotechnologies.

Institutional & Insider Ownership

48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 4.2% of Adverum Biotechnologies shares are held by insiders. Comparatively, 6.5% of Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Adverum Biotechnologies and Genetic Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adverum Biotechnologies	N/A	-90.38%	-51.37%
Genetic Technologies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Adverum Biotechnologies and Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adverum Biotechnologies	0	0	4	0	3.00
Genetic Technologies	0	0	0	0	N/A

Adverum Biotechnologies currently has a consensus price target of $29.00, suggesting a potential upside of 281.58%. Given Adverum Biotechnologies’ higher probable upside, research analysts clearly believe Adverum Biotechnologies is more favorable than Genetic Technologies.

Summary

Genetic Technologies beats Adverum Biotechnologies on 6 of the 10 factors compared between the two stocks.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.